<DOC>
	<DOCNO>NCT02723630</DOCNO>
	<brief_summary>This randomize , single dose , open-label , three-treatment period crossover study healthy participant determine whether 2 test lot 10-mg capsule vary level lenvatinib Type-C crystal bioequivalent reference lot 10-mg capsule .</brief_summary>
	<brief_title>Bioequivalence Study Evaluate Impact Varying Crystalline Polymorph Forms Commercial Oral Capsule Formulation 10-mg Lenvatinib Healthy Volunteers</brief_title>
	<detailed_description>The study consist 2 phase : Prerandomization Randomization . The Prerandomization Phase 2 period : Screening Baseline . The Randomization Phase consist three 6-day long Treatment Periods Treatment Period separate 1-day long Baseline . Sixty participant evenly randomize 1 6 possible treatment sequence ( A , B , C , D , E , F ) . The 3 treatment vary level crystalline polymorph Type-C present drug product batch use arm , respectively : Treatment 1 - low Type-C crystal level le 12 % ; Treatment 2 - reference Type-C crystal level 12 % 26 % ; Treatment 3 - high Type-C crystal level great 26 % .</detailed_description>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Healthy male female participant age great equal 18 year less equal 55 year old 2 . Nonsmokers smoker smoke 10 cigarette per day 3 . BMI great equal 18 less equal 32 kg/m2 Screening 4 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin ) 5 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( i.e. , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) 6 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( e.g. , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , participant must agree use doublebarrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week dose must continue use contraceptive study 30 day study drug discontinuation . 7 . Male participant must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 30 day study drug discontinuation . 8 . Provide write informed consent 1 . Clinically significant illness require medical treatment within 8 week Screening clinically significant infection require medical treatment within 4 week dose 2 . Evidence disease may influence outcome study within 4 week prior dose , e.g. , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , participant congenital abnormality metabolism 3 . Any history GI surgery may affect pharmacokinetic profile lenvatinib e.g. , hepatectomy , nephrotomy , digestive organ resection know Screening Baseline 4 . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , ECG finding , laboratory test result require medical treatment Screening Baseline 5 . Blood pressure measurement great 150/90 mm Hg . Confirmation obtain perform three measurement ( least 5 minute apart ) yield mean value . Participants may enrol stable dose single antihypertensive drug least 30 day prior first dose study drug intend change dose drug study . 6 . A prolonged QTcF interval ( QTcF great 450 m ) demonstrate ECG Screening Baseline 7 . Known history clinically significant drug allergy Screening Baseline 8 . Known history food allergy presently experience significant seasonal perennial allergy Screening Baseline know history sensitivity component test product 9 . Known human immunodeficiency virus positive Screening 10 . Active viral hepatitis ( A , B , C ) demonstrate positive serology Screening 11 . History drug alcohol dependency abuse within 2 year prior Screening positive urine drug test Screening Baseline 12 . Intake grapefruit grapefruitcontaining beverage food within 72 hour prior dose 13 . Intake medication know strong inhibitor inducer CYP450 3A4 metabolize enzyme within 2 week prior dose 14 . Currently enrol another clinical trial use investigational drug device within 30 day precede informed consent 15 . Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week dose 16 . Engagement strenuous exercise within 2 week prior checkin ( e.g. , marathon runner , weight lifter ) 17 . Any condition would make participant , opinion investigator sponsor unsuitable study likely complete study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Lenvima</keyword>
	<keyword>E7080</keyword>
</DOC>